Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER. Read more about Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER.
Clinicopathological and prognostic significance of interleukin-8 expression and its relationship to KRAS mutation in lung adenocarcinoma. Read more about Clinicopathological and prognostic significance of interleukin-8 expression and its relationship to KRAS mutation in lung adenocarcinoma.
FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium. Read more about FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium.
Low-dose inhalation of interleukin-2 bio-chemotherapy for the treatment of pulmonary metastases in melanoma patients. Read more about Low-dose inhalation of interleukin-2 bio-chemotherapy for the treatment of pulmonary metastases in melanoma patients.
Combined effects of endogenous sex hormone levels and mammographic density on postmenopausal breast cancer risk: results from the Breakthrough Generations Study. Read more about Combined effects of endogenous sex hormone levels and mammographic density on postmenopausal breast cancer risk: results from the Breakthrough Generations Study.
Collagen type XI α1 facilitates head and neck squamous cell cancer growth and invasion. Read more about Collagen type XI α1 facilitates head and neck squamous cell cancer growth and invasion.
A reanalysis of cancer mortality in Canadian nuclear workers (1956-1994) based on revised exposure and cohort data. Read more about A reanalysis of cancer mortality in Canadian nuclear workers (1956-1994) based on revised exposure and cohort data.
A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer. Read more about A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer.
A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer. Read more about A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer.
Recognising the benefits and harms of breast cancer screening: an opportunity to target improvement. Read more about Recognising the benefits and harms of breast cancer screening: an opportunity to target improvement.
